Straits Times Index
3,289.42 -23.93 (-0.72%) S&P 500
5,300.71 +54.03 (+1.03%) Dow
39,826.10 +267.99 (+0.68%) Nasdaq
16,728.66 +217.48 (+1.32%) Bitcoin USD
65,276.70 +3,917.14 (+6.38%) CMC Crypto 200
1,373.02 +105.08 (+8.29%)
Genomma Lab Internacional, S.A.B. de C.V. (LABB.MX)
| Previous close | 16.96 |
| Open | 16.99 |
| Bid | 17.19 x 50000 |
| Ask | 17.21 x 194200 |
| Day's range | 16.95 - 17.55 |
| 52-week range | 12.39 - 17.70 |
| Volume | |
| Avg. volume | 3,464,322 |
| Market cap | 16.306B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 14.96 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.78 (4.64%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | N/A |
- PR Newswire
Marzam's New Strategy Will Focus on Strengthening the Company's Position within Pharmaceutical Sector
Mexico's pharmaceutical and personal care industry is undergoing significant changes with the strategic moves announced by Genomma Lab International, S.A.B. de C.V. (B.M.V.: LABB) regarding its agreement to redeem capital in Marzam.
- PR Newswire
Agreement Signed for Share Redemption in Marzam
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies in Mexico with an expanding international presence, provides an update on the initiative to divest "non-core" assets and increase focus on its core brands and businesses.
- PR Newswire
Genomma Lab Internacional Announces Results for the First Quarter 2024
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with International Financial Reporting Standards (IFRS), unless otherwise mentioned.
